Mutation screening of human 5-HT(2B) receptor gene in early-onset obsessive-compulsive disorder

Molecular and Cellular Probes

Volumn 14, Issue 1, 2000, Pages 47-52

  Kim, S J ^a   Veenstra Vanderweele, J ^a   Hanna, G L ^b   Gonen, D ^a   Leventhal, B L ^a   Cook, Jr ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

HTR2B; Linkage; Marker; Mutation; Obsessive compulsive disorder; Polymorphism

Indexed keywords

SEROTONIN 2B RECEPTOR;

ADOLESCENT; ARTICLE; AUTISM; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC LINKAGE; GENETIC SCREENING; HUMAN; HUMAN CELL; INTRON; NUCLEOTIDE SEQUENCE; OBSESSION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; SCHOOL CHILD;

EID: 0034105758     PISSN: 08908508     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcpr.1999.0281     Document Type: Article

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Association. 1994.
2. Goodman W. K., Price L. H., Rasmussen S. A., Delgado P. L., Heninger G. R., Charney D. S. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Archives of General Psychiatry. 46:1989;36-44.
3. Jenike M. A., Baer L., Summergrad P., Minichiello W. E., Holland A., Seymour R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. American Journal of Psychiatry. 147:1990;923-928.
4. Riddle M. A., Scahill L., King R. A., Hardin M. T., Anderson G. M., Ort S. I. et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 31:1992;1062-1069.
5. Jenike M. A. Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. Psychopharmacology Bulletin. 29:1993;487-499.
6. Piggot T. A., Seay S. M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry. 60:1999;101-106.
7. Blier P., de Montigny C. Possible serotoÍnergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biological Psychiatry. 44:1998;313-323.
8. Young C. R., Bostic J. Q., McDanald C. L. Clozapine and refractory obsessive-compulsive disorder: a case report. Journal of Clinical PsychoÍpharmacology. 14:1994;209-211.
9. Giakas W. J. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. American Journal of Psychiatry. 152:1995;1097-1098.
10. Jacobsen F. M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Journal of Clinical Psychiatry. 56:1995;423-429.
11. McDougle C. J., Rleischmann R. L., Epperson C. N., Wasylink S., Leckman J. F., Price L. H. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. Journal of Clinical Psychiatry. 56:1995;526-528.
12. Ravizza L., Barzega G., Bellino S., Bogetto F., Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive- compulsive disorder (OCD). Psychopharmacology Bulletin. 32:1996;677-682.
13. Saxena S., Wang D., Bystritsky A., Baxter, Jr L. R. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry. 57:1996;303-306.
14. Stein D. J., Bouwer C., Hawkridge S., Emsley R. A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. Journal of Clinical Psychiatry. 58:1997;119-122.
15. Hanes K. R. Serotonin, psilocybin, and body dysmorphic disorder: a case report. Journal of Clinical Psychopharmacology. 16:1996;188-189.
16. Moreno F. A., Delgado P. L. Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry. 145:1997;1037-1038.
17. Delgado P. L., Moreno F. A. Hallucinogens, serotonin and obsessive-compulsive disorder. Journal of Psychoactive Drugs. 30:1998;359-366.
18. Schmuch K., Ullmer C., Engels P., Lubbert H. Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS letters. 342:1994;85-90.
19. Kursar J. D., Nelson D. L., Wainscott D. B., Baez M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine 2B receptor. Molecular Pharmacology. 46:1994;227-234.
20. 2Breceptor gene maps to 2q36.3-2q37.1. Genomics. 32:1996;172-173.
21. Bonhaus D. W., Bach C., DeSouza A., Salazar F. H., Matsuoka B. D., Zuppan P. et al. The pharmacology and distribution of human 5-hydroxytryptamine 2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. British Journal of Pharmacology. 115:1995;622-628.
22. Choi D. S., Ward S. J., Messaddeq N., Launay J., Maroteaux L. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardial cells. Development. 124:1997;1745-1755.
23. Kennett G. A., Wood M. D., Bright F., Cilia J., Piper D. C., Gager T. et al. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. British Journal of Pharmacology. 117:1996;427-434.
24. Duxon M. S., Kennett G. A., Lightowler S., Blackburn T. R., Fone K. C. F. Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology. 36:1997;601-608.
25. Kennett G. A., Ainsworth K., Trail B., Blackburn T. P. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology. 36:1997;233-239.
26. Di Matteo V., Di Giovanni G., Di Mascio M., Esposito E. Selective blockade of serotonin 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology. 37:1998;265-272.
27. Lenane M. C., Swedo S. E., Leonard H., Pauls D. L., Sceery W., Rapoport J. L. Psychiatric disorders in first degree relatives of children and adolescents with obsessive compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 29:1990;407-412.
28. Nicolini H., Hanna G. L., Baxter L., Schwartz J., Weissbacker K., Spence M. A. Segregation analysis of obsessive compulsive and associated disorders. Ursus Medicus. 1:1991;25-28.
29. Riddle M. A., Scahill L., King R., Hardin M. T., Towbin K. E., Ort S. I. et al. Obsessive compulsive disorder in children and adolescents: phenomenology and family history. Journal of the American Academy of Child and Adolescent Psychiatry. 29:1990;766-772.
30. Orvaschel H. Schedule for Affective Disorders and Schizophrenia for School Aged Children-Epidemiologic Version(K-SADS-E), 4th ed. Philadelphia: Medical College of Pennsylvania. 1987.
31. Pauls D. L., Hurst C. R. Schedule for Tourette and Other Behavioral Syndromes (Adult on Child Form, Version C1). New Haven: Child Study Center, Yale University School of Medicine. 1991.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised (DSM-III-R). Washington, DC: American Psychiatric Association. 1987.